Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
申请人:Matsumoto Takahiro
公开号:US20090048263A1
公开(公告)日:2009-02-19
A compound represented by the formula (I) or a salt thereof; and an agent for protecting a brain/neuronal cell or a therapeutic agent for sleep disorder comprising the compound or salt: wherein Z represents an oxygen or sulfur; R
1
represents an aryl or heterocyclic group which may be substituted, provided that R
1
is not a 3-ethyl-6-methoxy-2-methyl-5-naphthalen-1-yl group; R
1a
represents a hydrogen atom, a hydrocarbon group which may be substituted, a hydroxyl group or the like; R
2
represents a piperidin-1,4-diyl or piperazin-1,4-diyl which may be substituted; R
3
represents a bivalent group which is formed by removing two hydrogen atoms from a benzene ring or 6-membered aromatic heterocyclic ring which may have a substituent, provided that R
3
is not a pyridazin-3,6-diyl; and R
4
represents a group which is formed by removing one hydrogen atom from a benzene ring or 5- to 6-membered heterocyclic ring which may be substituted, provided that the substituent on the heterocyclic ring is not a phenylethyl group which may be substituted when Z is sulfur.
BRAIN/NEURONAL CELL-PROTECTING AGENT, AND THERAPEUTIC AGENT FOR SLEEP DISORDER
申请人:Takeda Pharmaceutical Company Limited
公开号:EP1923388A1
公开(公告)日:2008-05-21
A compound represented by the formula (I) or a salt thereof; and an agent for protecting a brain/neuronal cell or a therapeutic agent for sleep disorder comprising the compound or salt: wherein Z represents an oxygen or sulfur; R1 represents an aryl or heterocyclic group which may be substituted, provided that R1 is not a 3-ethyl-6-methoxy-2-methyl-5-naphthalen-1-yl group; R1a represents a hydrogen atom, a hydrocarbon group which may be substituted, a hydroxyl group or the like; R2 represents a piperidin-1,4-diyl or piperazin-1,4-diyl which may be substituted; R3 represents a bivalent group which is formed by removing two hydrogen atoms from a benzene ring or 6-membered aromatic heterocyclic ring which may have a substituent, provided that R3 is not a pyridazin-3,6-diyl; and R4 represents a group which is formed by removing one hydrogen atom from a benzene ring or 5- to 6-membered heterocyclic ring which may be substituted, provided that the substituent on the heterocyclic ring is not a phenylethyl group which may be substituted when Z is sulfur.